These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1112 related articles for article (PubMed ID: 17234558)

  • 1. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
    D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
    Kamm MA; Sandborn WJ; Gassull M; Schreiber S; Jackowski L; Butler T; Lyne A; Stephenson D; Palmen M; Joseph RE
    Gastroenterology; 2007 Jan; 132(1):66-75; quiz 432-3. PubMed ID: 17241860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
    Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
    Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
    Sandborn WJ; Kamm MA; Lichtenstein GR; Lyne A; Butler T; Joseph RE
    Aliment Pharmacol Ther; 2007 Jul; 26(2):205-15. PubMed ID: 17593066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
    Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
    D'Haens G; Sandborn WJ; Barrett K; Hodgson I; Streck P
    Am J Gastroenterol; 2012 Jul; 107(7):1064-77. PubMed ID: 22565161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
    Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
    Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
    Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
    Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesalamine with MMX technology for the treatment of ulcerative colitis.
    Schreiber S; Kamm MA; Lichtenstein GR
    Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):299-314. PubMed ID: 19072380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
    Hanauer S; Schwartz J; Robinson M; Roufail W; Arora S; Cello J; Safdi M
    Am J Gastroenterol; 1993 Aug; 88(8):1188-97. PubMed ID: 8338086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-matrix system mesalamine: to use or not to use.
    Kale-Pradhan PB; Pradhan RS; Wilhelm SM
    Ann Pharmacother; 2008 Feb; 42(2):265-9. PubMed ID: 18182473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.
    Prantera C; Kohn A; Campieri M; Caprilli R; Cottone M; Pallone F; Savarino V; Sturniolo GC; Vecchi M; Ardia A; Bellinvia S
    Aliment Pharmacol Ther; 2009 Nov; 30(9):908-18. PubMed ID: 19678813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
    Kruis W; Bar-Meir S; Feher J; Mickisch O; Mlitz H; Faszczyk M; Chowers Y; Lengyele G; Kovacs A; Lakatos L; Stolte M; Vieth M; Greinwald R
    Clin Gastroenterol Hepatol; 2003 Jan; 1(1):36-43. PubMed ID: 15017515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
    Sandborn WJ; Korzenik J; Lashner B; Leighton JA; Mahadevan U; Marion JF; Safdi M; Sninsky CA; Patel RM; Friedenberg KA; Dunnmon P; Ramsey D; Kane S
    Gastroenterology; 2010 Apr; 138(4):1286-96, 1296.e1-3. PubMed ID: 20064514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.
    Kamm MA; Lichtenstein GR; Sandborn WJ; Schreiber S; Lees K; Barrett K; Joseph R
    Inflamm Bowel Dis; 2009 Jan; 15(1):1-8. PubMed ID: 18671232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis.
    Safdi M; DeMicco M; Sninsky C; Banks P; Wruble L; Deren J; Koval G; Nichols T; Targan S; Fleishman C; Wiita B
    Am J Gastroenterol; 1997 Oct; 92(10):1867-71. PubMed ID: 9382054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.